Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Squamous Cell

Melanoma

Carcinoma, Renal Cell

Squamous Cell Carcinoma of Head and Neck

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Head and Neck Neoplasms

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Analgesics

Pembrolizumab

Interleukin-2

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

AB248 will be administered intravenously as a single agent

AB248 and pembrolizumab will be administered intravenously

AB248 will be administered intravenously as a single agent in disease specific cohorts

AB248 and pembrolizumab will be administered intravenously in disease specific cohorts

Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug

AB248

pembrolizumab

Clinical Operations

Medical Monitor

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥4 weeks after initial documentation of response.

Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.

Defined as the percentage of patients who have achieved CR, PR, or stable disease.

Defined as the time from first dose of AB248 to first documentation of radiographic disease progression or death, whichever occurs first

Defined as the time from first dose of AB248 to the date of death.

Defined as assessments for measuring maximum blood concentration of AB248

Defined as assessments for evaluating the Area Under the Concentration-Time Curve (AUC)

Defined as the time required for half of the drug to be eliminated from the blood

Defined as the volumetric enumeration of CD8+ T cells in whole blood as assessed by flow cytometry

Defined as changes in immune-staining for CD8+ T cells density in tumor tissue from patients providing paired biopsies.

Defined as the frequency of ADA formation for immunogenicity assessments evaluated during study treatment up until 30 days after the final dose of study treatment.

Spots Global Cancer Trial Database for ab248

Every month we try and update this database with for ab248 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ab248

Every month we try and update this database with for ab248 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ab248 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.